EDIT Q2 2023 Earnings — Editas Medicine, Inc. Revenue & Financial Results | Market Cap Arena

EDITEditas Medicine, Inc.

$256M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-54.6% YoY

Gross Profit

-$27M-931.5% margin

Operating Income

-$44M-1527.3% margin

Net Income

-$40M-1395.6% margin

EPS (Diluted)

$-0.56

QoQ Revenue Growth

-70.7%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$40M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$542M

Total Liabilities

$142M

Stockholders' Equity

$400M

Cash & Equivalents

$221M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$6M	-54.6%
Gross Profit	-$27M	-$37M	+27.9%
Operating Income	-$44M	-$54M	+18.7%
Net Income	-$40M	-$53M	+24.6%